R_2
Rheumatoid Arthritis Management
search
Rheumatoid Arthritis Management
See Also
Rheumatoid Arthritis
Rheumatoid Arthritis Diagnosis
Rheumatoid Arthritis Articular Signs
Rheumatoid Arthritis Extra-articular Signs
Felty's Syndrome
Rheumatoid Arthritis Antiinflammatory Medications
Rheumatoid Arthritis Remittive Agent
s
Approach
Assess Current disease activity
Morning Stiffness
Synovitis
Fatigue
C-Reactive Protein
Document Joint Damage
Joint Range of motion and deformities
XRay joint space narrowing and erosions
Functional status
Document Joint Extra-articular manifestations
Nodule
s
Pulmonary fibrosis
Vasculitis
Scales to grade current
Rheumatoid Arthritis
Severity
Clinical Disease Activity Index
(
CDAI
)
Simplified Disease Activity Index
(
SDAI
)
Management
Gene
ral
Non-Pharmacologic
Systemic and articular rest
Tobacco Cessation
Tobacco Smoking
is associated with more severe RA-related articular and extraarticular disease
Cardiovascular Risk
is significantly increased in RA
Overall
Cardiovascular Risk Reduction
is critical
Physiotherapy
Physical therapy and hand therapy for joint protection techniques
Local Heat Therapy
Local Cold Therapy
Exercise
s
Range of Motion
Conditioning
Strengthening
Exercise
s
Tai Chi
Assistive Device
s
Patient Education
Materials
Arthritis
Foundation
American College Rheumatology
Bob and Brad (Youtube)
Gene
ral
Exercise
s
https://www.youtube.com/watch?v=sVHJy24JjHo
Hand
Exercise
s
https://www.youtube.com/watch?v=TdhvUFFv1_A
Rheumatoid Arthritis Remittive Medication
s (
DMARDs
)
Most important agents in
Rheumatoid Arthritis
Methotrexate
is first-line preferred agent
Alternatives include
Leflunomide
,
Sulfasalazine
,
Plaquenil
Biologic and TNF agents are third-line agents in refractory cases
Consider tapering
DMARD
if in remission for at least 6 months (esp. if anti-citrullinated
Protein
negative)
In some cases
DMARDs
may be tapered off with maintained remission
Haschka (2016) Ann Rheum Dis 75(1):45-51 [PubMed]
Rheumatoid Arthritis Antiinflammatory Medications
(
NSAID
s,
COX2 Inhibitor
s)
Used in combination with
DMARDs
Limit use of
NSAID
s and
COX2 Inhibitor
s once on
DMARD
>1 month
Decrease to lowest effective dose (preferably use only as needed)
Best use is limiting
NSAID
S and
COX2 Inhibitor
s for exacerbations
Other medications
Atorvastatin
Showed modest benefit in clinical improvement
McCarey (2004) Lancet 363:2015-21 [PubMed]
Joint Replacement
Consider for severe joint damage with pain refractory to medical management
Management
Initial protocol
Indications: New moderate to severe seropositive
Rheumatoid Arthritis
Protocol: Start
Prednisone
Low dose protocol (preferred if adequate)
Prednisone
5-10 mg orally daily for 4-6 weeks
High dose tapering protocol
Prednisone
60 mg daily tapered weekly by 10 mg each week
Methotrexate
Start at 7.5-10 mg weekly and titrate to 15 mg weekly in the first 4-6 weeks
Folic Acid
1 mg daily
References
Michet (2012) Mayo POIM Conference, Rochester
Management
Emergency Department
Cardiopulmonary presentations
Myocardial Infarction
risk (RR 3)
Congestive Heart Failure
(RR 2)
Atrial Fibrillation
(RR 1.4)
Pulmonary fibrosis,
Pulmonary Hypertension
and
Right Heart Failure
Pulmonary Embolism
Pericardial Effusion
Pleural Effusion
Methotrexate
induced pulmonary toxicity
Infectious disease presentations
Immunosuppression
due to RA alone, in addition to medications (e.g. TNF agents,
Corticosteroid
s)
Pneumonia
(including opportunistic lung infections, fungal infections,
Legionella
,
Tuberculosis
)
Joint Pain
presentation
Exclude
Septic Arthritis
!
Diagnosis is often delayed in
Rheumatoid Arthritis
Immunocompromised
state results in underwhelming signs (afebrile, minimally
Inflamed joint
)
Aspirate suspected joints
Rheumatoid Arthritis
flare (after excluding
Septic Joint
)
Prednisone
taper from 60 mg to 10 mg over 2 weeks
Endotracheal Intubation
Atlantoaxial subluxation risk
Risk of secondary cervicomedullary compression and respiratory arrest
Temporomandibular Joint
Arthritis
Decreased mouth opening (see
LEMON Mnemonic
)
Intubation Approach
Maintain inline cervical stabilization during intubation
Use videolarygnoscopy or fiberoptics to aid intubation
References
Herbert, Orman, Berman in Herbert (2018) EM:Rap 18(4): 6
References
Pincus (1993) Rheum Dis Clin North Am 19:123-151 [PubMed]
Scott (2010) Lancet 376(9746):1094-108 [PubMed]
Wasserman (2011) Am Fam Physician 84(11): 1245-52 [PubMed]
Wasserman (2018) Am Fam Physician 97(7): 455-62 [PubMed]
Type your search phrase here